Ferring Japan Starts Own Marketing Of Fertility Drug
This article was originally published in PharmAsia News
Tokyo-based Ferring Pharma, a Japanese subsidiary of the Swiss drug maker Ferring Pharmaceuticals, announced July 7 that it will begin its own marketing efforts beginning July 28. Its first product is the fertility drug human menopausal gonadotropin (hMG) injection 75IU. Ferring Pharma has been marketing an ulcerative colitis drug and human growth hormone products through partners, and the company's annual sales are ¥25 billion. With the start of its own marketing, Ferring estimates sales to reach ¥30 billion by 2017, accounting for 10 percent of worldwide sales. The company will focus on infertility and urology as it looks to further widen its product pipeline. Ferring Pharma also started jointly marketing enuresis drug desmopressin with Kyowa Hakko in July. (Click here for more - Japanese language
You may also be interested in...
The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.